Evidence map›Paper›PMID 32310862›Full record

ReviewThe American Journal of dermatopathology2020

Melanoma Ex Blue Nevus With GNA11 Mutation and BAP1 Loss: Case Report and Review of the Literature.

Li-Wei Chang, Viktoryia Kazlouskaya, Rashek Kazi, Diwakar Davar, Robert L Ferris, Jonhan Ho, Arivarasan Karunamurthy, Jaroslaw J Jedrych, Yuri L Bunimovich

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in The American Journal of dermatopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Blue nevus-like melanoma: A rare entity.Dermatology online journal · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Li-Wei ChangDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Viktoryia KazlouskayaDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Rashek KaziDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Diwakar DavarHillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and.
Robert L FerrisHillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and.
Jonhan HoDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Arivarasan KarunamurthyDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Jaroslaw J JedrychDepartment of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Yuri L BunimovichDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA.
University of Pittsburgh Medical Center · USUPMC Hillman Cancer Center · USJohns Hopkins Medicine · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

Cutaneous melanomas may demonstrate a variety of histopathological features and genetic abnormalities. Melanomas that arise in the setting of blue nevi, also known as "malignant blue nevus" or melanoma ex blue nevus (MBN), share a similar histopathological and mutational profile with uveal melanoma. Most uveal melanomas show characteristic GNA11 or GNAQ mutations; additional BAP1 mutation or loss is associated with the highest risk of metastasis and worst prognosis. However, the significance of BAP1 loss in melanomas ex blue nevus remains unclear. We present a case of MBN arising from the scalp of a 21-year-old woman. The diagnosis was established on histopathological findings demonstrating a markedly atypical melanocytic proliferation with increased mitotic activity, necrosis, and a focus of angiolymphatic invasion. Immunohistochemical analysis demonstrated the absence of BAP1 nuclear expression within tumor cells. Next generation sequencing detected GNA11 Q209L mutation and BAP1 loss (chromosome 3p region loss), supporting the diagnosis. We reviewed another 21 MBN cases with reported BAP1 status from the literature. MBN with BAP1 loss presented at a younger average age (41 vs. 61 years), demonstrated larger average lesion thickness (9.0 vs. 7.3 mm), and had a higher rate of metastasis (50% vs. 33%) compared with BAP1-retained MBN. BAP1 expression studies may assist in the diagnosis and management of MBN, but further research is needed.

Indexed as

FemaleGTP-Binding Protein alpha SubunitsHumansMelanomaNevus, BlueScalpSkin NeoplasmsTumor Suppressor ProteinsUbiquitin ThiolesteraseYoung AdultBAP1 protein, humanGNA11 protein, humanGTP-Binding Protein alpha SubunitsTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID32310862
PMCPMC7572824
OpenAlexW3016351860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.